6,678 trials
Multiple Sclerosis · Clinically Isolated Syndrome
Primary: Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First…
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate (ORR) — 70.6 Percentage of Participants
SLE · Lupus Nephritis · SGLT2 Inhibitors
Primary: Effect of Dapagliflozin Compared to Placebo on Renal Function After One Year — 128; 114; 115.7; 100.3 mL/min/1.73 m²
Cardiovascular Diseases
Primary: Difference in Mitochondrial Respiratory Function — 2.29; -11.24; 44.88 pmols/s/mg — p=0.9530
Ankle Surgery · Foot Surgery
Primary: Block Duration — 18.2 hours
Overactive Bladder
Primary: Participant Discomfort Related to BTX-A Injection — 3.2; 3.6 score on a scale — p=0.21
Healthy Lactating Women
Primary: Daily Infant Dose — 0.0331; 0.0337; 0.0002 Milligrams per day
HIV-1-infection · Methamphetamine-dependence
Primary: HIV Transcription (Cell-associated HIV RNA) in Peripheral Blood — 10.45; 57.38 copies/million cells
Depression · Dual Diagnosis · Drug Addiction
Primary: Hamilton Depression Rating Scale (HAMD) Scores — 16.76; 17.65; 1.67; 16.24 score on a scale
HIV Infections · Contraception · Drug-drug Interaction
Primary: Hormonal Contraceptive Concentrations — 589; 1293; 542; 1761 pg/mL — p=0.306
Bipolar Disorder · Panic Disorder · Generalized Anxiety Disorder
Primary: Clinician Global Improvement Scale (CGI-21) — 7.8; 3.4 units on a scale
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
Kidney Transplant; Complications · Toxicity · Drug Toxicity
Primary: Change in Neurocognitive Side Effects — 1.2; 0.2; 1.0; 1.26 score on a scale
Dry Eye
Primary: SANDE Questionnaire — -7.2; -2.2 score
Inflammatory Bowel Diseases · Crohn Disease · Ulcerative Colitis
Primary: Change in Cell Mediated Immunity — 33; 33; 33; 50 cells per million — p=0.16